Phase 2 Review for Zoetis’ proposed acquisition of Neogen Genomics

The ACCC has announced that Zoetis Holdings LLC’s proposed acquisition of Neogen Corporation’s global animal genomic testing business (Neogen Genomics) could substantially lessen competition and requires Phase 2 review.

View ACCC media release.

View ACCC Acquisitions register.

See my phase 2 review page.

Next
Next

Phase 2 Review for proposed Saipem Subsea7 merger